Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 3

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Greenwich LifeSciences Inc.

Migraine

Recruiting

Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.